Published in Br J Pharmacol on May 14, 2009
Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54
Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol (2010) 1.34
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med (2011) 1.28
APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care (2010) 1.08
Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol (2011) 1.02
Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care (2010) 1.00
Activated protein C action in inflammation. Br J Haematol (2009) 0.98
Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) (2014) 0.97
Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice. PLoS One (2012) 0.82
Activated protein C inhalation: a novel therapeutic strategy for acute lung injury. Med Sci Monit (2011) 0.79
Bilateral iliac and popliteal arterial thrombosis in a child with focal segmental glomerulosclerosis. Korean J Pediatr (2016) 0.78
Levels of protein C and soluble thrombomodulin in critically ill patients with acute kidney injury: a multicenter prospective observational study. PLoS One (2015) 0.76
Mediators and receptors in the resolution of inflammation: drug targeting opportunities. Br J Pharmacol (2009) 0.75
Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis. Exp Ther Med (2015) 0.75
Dysregulation of pulmonary endothelial protein C receptor and thrombomodulin in severe falciparum malaria-associated ARDS relevant to hemozoin. PLoS One (2017) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
The acute respiratory distress syndrome. N Engl J Med (2000) 25.38
Thrombin signalling and protease-activated receptors. Nature (2000) 9.27
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 5.86
Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol (1989) 5.41
Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science (2002) 5.35
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet (2007) 5.23
Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost (2005) 4.64
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (2005) 3.85
Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood (2004) 3.58
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem (2005) 3.54
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med (2007) 3.34
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med (2007) 3.31
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem (2001) 3.31
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med (2008) 3.28
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med (1990) 3.04
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 3.02
Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry (1977) 2.96
The interactions between inflammation and coagulation. Br J Haematol (2005) 2.92
Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 2.57
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med (2004) 2.45
Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 2.37
Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol (2007) 2.35
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med (2002) 2.22
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med (2007) 2.20
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology (2006) 2.19
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost (2006) 1.98
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood (2004) 1.95
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol (2007) 1.95
Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci U S A (2007) 1.87
PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem (2005) 1.83
Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem (2005) 1.81
Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation (2004) 1.81
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Disseminated intravascular coagulation in sepsis. Chest (2005) 1.64
A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem (1976) 1.64
Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood (1989) 1.64
Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med (2003) 1.62
Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med (2007) 1.61
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med (2008) 1.60
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury. Intensive Care Med (2007) 1.57
Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem (2000) 1.54
Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol (1991) 1.54
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol (2000) 1.51
Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol (2005) 1.46
Expression and function of the endothelial protein C receptor in human neutrophils. Blood (2003) 1.45
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost (2002) 1.43
The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax (2007) 1.41
Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood (2006) 1.38
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood (2003) 1.35
Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med (2005) 1.33
Identification of functional endothelial protein C receptor in human plasma. J Clin Invest (1997) 1.31
Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem (2000) 1.29
Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol (2006) 1.29
Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation (2001) 1.27
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood (2007) 1.26
Plasma thrombomodulin in health and diseases. Blood (1990) 1.24
The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol (2000) 1.23
Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A). Thromb Diath Haemorrh (1960) 1.23
Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood (2003) 1.21
Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med (2006) 1.20
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg (2000) 1.17
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res (2006) 1.17
Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2006) 1.16
Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med (2000) 1.11
Activated protein C. J Thromb Haemost (2007) 1.10
Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood (2004) 1.09
Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med (2005) 1.09
Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med (2004) 1.09
Effects of drotrecogin alfa (activated) in human endotoxemia. Shock (2004) 1.07
Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med (2007) 1.07
Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. Crit Care (2006) 1.05
Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A (2003) 1.05
Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem (2007) 1.04
"All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) (2007) 1.00
Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol (2003) 0.99
Regulation of inflammatory responses by natural anticoagulants. Immunol Rev (2001) 0.99
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol (2006) 0.98
The protein C pathway: implications for the design of the RESPOND study. Crit Care (2007) 0.96
Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol (2006) 0.95
Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C. Thromb Haemost (2003) 0.94
Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells. Int J Hematol (1998) 0.93
Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med (2007) 0.93
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 48.03
Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med (2004) 11.78
Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med (2002) 6.17
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med (2005) 5.76
Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol (2007) 5.66
Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med (2011) 5.24
An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol (2011) 4.65
Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol (2008) 3.93
Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med (2009) 3.86
Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A (2009) 3.84
Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med (2003) 3.74
Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg (2007) 3.49
Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med (2014) 3.39
Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med (2006) 3.38
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med (2007) 3.31
Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med (2008) 3.28
Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA (2005) 3.21
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest (2009) 3.08
Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A (2010) 3.05
Nonventilatory treatments for acute lung injury and ARDS. Chest (2007) 3.02
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 3.02
Postobstructive pulmonary edema: a case for hydrostatic mechanisms. Chest (2007) 2.97
Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev (2003) 2.95
Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med (2007) 2.79
Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells (2010) 2.72
Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med (2005) 2.67
Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med (2004) 2.66
Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med (2013) 2.66
Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med (2006) 2.63
Effects of recruitment maneuvers in patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure. Crit Care Med (2003) 2.63
Clinical practice. Acute pulmonary edema. N Engl J Med (2005) 2.62
Acute kidney injury: an increasing global concern. Lancet (2013) 2.61
Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med (2006) 2.61
Transfusion-related acute lung injury: a review. Chest (2004) 2.56
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med (2011) 2.55
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med (2009) 2.52
Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med (2004) 2.51
Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest (2006) 2.50
Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med (2004) 2.49
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med (2006) 2.47
Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem (2004) 2.42
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis (2013) 2.42
Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells (2011) 2.41
Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs. Am J Respir Crit Care Med (2002) 2.40
Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest (2006) 2.40
Active and passive cigarette smoking and acute lung injury after severe blunt trauma. Am J Respir Crit Care Med (2011) 2.39
Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 2.37
Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med (2013) 2.34
Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol (2002) 2.30
Alveolar epithelial ion and fluid transport: recent progress. Am J Respir Cell Mol Biol (2006) 2.20
Informed consent in research to improve the number and quality of deceased donor organs. Crit Care Med (2011) 2.18
Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med (2013) 2.17
Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest (2009) 2.17
Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol (2004) 2.15
Racial and ethnic disparities in mortality from acute lung injury. Crit Care Med (2009) 2.14
Therapeutic strategies for severe acute lung injury. Crit Care Med (2010) 2.12
Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice. Exp Lung Res (2004) 2.12
Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol (2002) 2.10
Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome. Crit Care Med (2016) 2.08
Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med (2015) 2.07
Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol (2013) 2.04
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2010) 2.03
Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax (2012) 2.02
Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol (2011) 2.00
Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha. Am J Respir Crit Care Med (2003) 1.98
Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2003) 1.98
Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med (2003) 1.96
Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2007) 1.92
Prognostic value of the pulmonary dead-space fraction during the first 6 days of acute respiratory distress syndrome. Respir Care (2004) 1.92
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol (2012) 1.90
Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem (2003) 1.90
Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. Am J Physiol Lung Cell Mol Physiol (2005) 1.87
Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem (2010) 1.86
Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients. Crit Care Med (2011) 1.86
Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway. J Biol Chem (2005) 1.86
Overview of interleukin-2 function, production and clinical applications. Cytokine (2004) 1.86
Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol (2005) 1.83
Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2003) 1.82
Stimulation of alveolar epithelial fluid clearance in human lungs by exogenous epinephrine. Crit Care Med (2006) 1.81
Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med (2012) 1.81
Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv (2010) 1.78
Accuracy of physiologic dead space measurements in patients with acute respiratory distress syndrome using volumetric capnography: comparison with the metabolic monitor method. Respir Care (2005) 1.75
Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol (2012) 1.74
Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circ Res (2008) 1.73
Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med (2007) 1.73
Science review: mechanisms of ventilator-induced injury. Crit Care (2002) 1.71
Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med (2010) 1.71
Age-, sex-, and race-based differences among patients enrolled versus not enrolled in acute lung injury clinical trials. Crit Care Med (2010) 1.71
One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. Intensive Care Med (2014) 1.70
Acute effects of tidal volume strategy on hemodynamics, fluid balance, and sedation in acute lung injury. Crit Care Med (2005) 1.70
Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care (2008) 1.69
The value of positive end-expiratory pressure and Fio₂ criteria in the definition of the acute respiratory distress syndrome. Crit Care Med (2011) 1.64
The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol (2010) 1.63
Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells (2014) 1.63